Posted by Michael Wonder on 24 Feb 2021
PHARMAC knew of epilepsy drug change risks within some patients, but went ahead with switch
24 February 2021 - PHARMAC knew there were clinical reasons some epilepsy patients would not tolerate a change to their medicines.
But the drug buying agency went ahead with a switch that forced more than 10,000 people to change brands of the anti-epileptic drug lamotrigine anyway.
